---
title: "Asahi Kasei to Acquire Veloxis Pharmaceuticals for $1.3 Billion"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/273676767.md"
datetime: "2026-01-26T09:09:47.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/273676767.md)
  - [en](https://longbridge.com/en/news/273676767.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/273676767.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/273676767.md) | [English](https://longbridge.com/en/news/273676767.md)


# Asahi Kasei to Acquire Veloxis Pharmaceuticals for $1.3 Billion

Asahi Kasei is set to acquire Veloxis Pharmaceuticals Inc., a U.S.-based pharmaceutical company, through its Danish subsidiary. The transaction involves a voluntary tender offer for all ordinary shares and warrants of Veloxis Pharmaceuticals A/S, which owns 100% of Veloxis. The deal, valued at approximately USD 1.3 billion, is intended to accelerate Asahi Kasei’s transformation into a global health care company by strengthening its pharmaceutical presence in the U.S. market and creating synergies between its existing operations in Japan and Asia and Veloxis’ business platform in the United States. The acquisition aims to boost licensing activities, expand the pipeline of new pharmaceuticals, and enhance access to innovation and clinical practices in the U.S. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Asahi Kasei Corporation published the original content used to generate this news brief on January 26, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### 相關股票

- [iShares Global Healthcare (IXJ.US)](https://longbridge.com/zh-HK/quote/IXJ.US.md)
- [First Trust NYSE Arca Biotech Index Fd (FBT.US)](https://longbridge.com/zh-HK/quote/FBT.US.md)
- [VG Health (VHT.US)](https://longbridge.com/zh-HK/quote/VHT.US.md)
- [ALPS Medical Breakthrough (SBIO.US)](https://longbridge.com/zh-HK/quote/SBIO.US.md)
- [Health Care Select Sector SPDR (XLV.US)](https://longbridge.com/zh-HK/quote/XLV.US.md)
- [Asahi Kasei Corporation (3407.JP)](https://longbridge.com/zh-HK/quote/3407.JP.md)
- [SPDR S&P Biotech (XBI.US)](https://longbridge.com/zh-HK/quote/XBI.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/zh-HK/quote/BBH.US.md)
- [Proshares Ultra Nasdaq Biotech (BIB.US)](https://longbridge.com/zh-HK/quote/BIB.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/zh-HK/quote/IBB.US.md)
- [Vertex Pharma (VRTX.US)](https://longbridge.com/zh-HK/quote/VRTX.US.md)
- [Ark Genomic Revolution ETF (ARKG.US)](https://longbridge.com/zh-HK/quote/ARKG.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/zh-HK/quote/PBE.US.md)
- [iShares US Pharma (IHE.US)](https://longbridge.com/zh-HK/quote/IHE.US.md)
- [Asahi Kasei (AHKSY.US)](https://longbridge.com/zh-HK/quote/AHKSY.US.md)

## 相關資訊與研究

- [Glenmark Pharma to directly commercialize and distribute Ryaltris in U.S. effective](https://longbridge.com/zh-HK/news/281370208.md)
- [Vertex Pharmaceuticals Says US FDA Approves Label Expansion for Alyftrek, Trikafta](https://longbridge.com/zh-HK/news/281365753.md)
- [Vertex Pharmaceuticals Inc - FDA expands indication for trikafta in cf patients ages 2 and older](https://longbridge.com/zh-HK/news/281371049.md)
- [Elite Pharmaceuticals launches generic methadone tablets; 2025 category sales ~$22M](https://longbridge.com/zh-HK/news/281522306.md)
- [EXCLUSIVE: Penny Stock Scienture Reports Revenue Surge, Expanding Market Access In 2025](https://longbridge.com/zh-HK/news/281015927.md)